PH

CENTRAL AMERICA NICKEL ANNOUNCES FILING OF A PROVISIONAL PATENT APPLICATION FOR LITHIUM EXTRACTION AND RECOVERY

Retrieved on: 
Thursday, November 9, 2023
Lithium, PH, International Energy Agency, EV, Acquisition, Lithium carbonate, Research, Extraction, McGill University, Acid, Mineral, CO2, École polytechnique, Sonication, Longevity

MONTREAL, Nov. 9, 2023 /PRNewswire/ -- Central America Nickel Inc. (the "Company" or "CAN") is pleased to announce it has filed a provisional patent application No.

Key Points: 
  • MONTREAL, Nov. 9, 2023 /PRNewswire/ -- Central America Nickel Inc. (the "Company" or "CAN") is pleased to announce it has filed a provisional patent application No.
  • 63/596413 titled "Process for Extraction of Lithium Values from Spodumene Feedstocks."
  • The provisional application relates to a novel process for the extraction and recovery of lithium values from a spodumene feedstock in high yield and purity, with the use of CAN's proprietary Ultrasound Assisted Extraction technology (UAEx) as intensification approach.
  • The successful application of ultrasound-assisted leaching, the UAEx, has been a significant leap in lithium recovery from spodumene feedstocks.

DASYNOC™ Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL® Uptake is Significantly More Impaired than Previously Understood

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, PH, FDA, AUC, PPI, Omeprazole, Physician, CML, HIV disease progression rates, Dasatinib, Risk, TKI, Blood, Patient, Death, Solubility, Pharmaceutical industry, Cmax

Xspray has demonstrated that in the DASYNOC CO-PPI Study, DASYNOC’s uptake into blood was not affected 10 hours after taking omeprazole (107 % of intended AUC0-24h and 86% of intended Cmax).

Key Points: 
  • Xspray has demonstrated that in the DASYNOC CO-PPI Study, DASYNOC’s uptake into blood was not affected 10 hours after taking omeprazole (107 % of intended AUC0-24h and 86% of intended Cmax).
  • However, in the SPRYCEL CO-PPI Study, the uptake of SPRYCEL was significantly reduced 10 hours after taking omeprazole (only 12% of the intended AUC0-24h and 4% of the intended Cmax).
  • “We recently published that CML patients, concomitantly treated with TKIs and PPIs, are at a statistically significant 3.5-fold increased risk of death.
  • SPRYCEL was approved in 2006 by the FDA and is the market leading branded product that revolutionized the treatment of CML.

KMOU Researchers Propose an Organic-Solvent-Free Method for Producing Nanosized Vaterite

Retrieved on: 
Wednesday, November 8, 2023
PH, Ageing, Human, Professor, Carbon, Calcium carbonate, Sucrose, Cosmetics, Environmental engineering, Particle size, Environment, Growth, Vaterite, Solvent, Noetics, Calcium, Ruthenium-iridium nanosized coral, Seawater, Solubility, Limestone

BUSAN, South Korea, Nov. 8, 2023 /PRNewswire/ -- Vaterite is one of the three forms of calcium carbonate, along with calcite and aragonite. Nanosized vaterite is valuable for various applications, such as drug delivery, cosmetics, and bone defect filling, owing to its biocompatibility, high porosity, solubility, and large specific surface area.

Key Points: 
  • Therefore, there is an urgent need for a method that circumvents these challenges, is cost-effective, and results in environmentally friendly synthesis of vaterite.
  • Addressing these concerns associated with vaterite production, a team of researchers from Korea Maritime & Ocean University, led by Professor Myoung-Jin Kim of the Department of Environmental Engineering, has reported an indirect carbonation method that uses seawater to produce nanosized vaterite.
  • Each step of the proposed method contributes to vaterite production and particle size reduction, with optimal conditions resulting in nanosized particles with 100% vaterite.
  • The proposed method can be highly advantageous from economic and environmental viewpoints for the mass production of nanosized vaterite, without requiring a substantial amount of organic solvent," concludes Prof. Kim.

Nine Mile Metals Receives Final Water Baseline Water and Sediments Certified Lab Analysis Report From GEMTEC and Finalizes Engineer Site Plan Analysis

Retrieved on: 
Tuesday, November 7, 2023
Flo, PH, KQ9, QA/QC, Temperature, Science, UAV, Lidar, Metal, News, Project, Final, CSE, Natural resource, National instrument, OTCQB, Baseline, Development, Reclaim, Zinc, NB, FSE, Mining, Water quality, Bathurst Mining Camp, Canal, Surveying, Environmental remediation, Engineering

GEMTEC has delivered Nine Mile Metals its Final Report complete with the Baseline Water & Sediments Lab Certified Results to act as the Project’s baseline levels for its upcoming Bulk Sample Project.

Key Points: 
  • GEMTEC has delivered Nine Mile Metals its Final Report complete with the Baseline Water & Sediments Lab Certified Results to act as the Project’s baseline levels for its upcoming Bulk Sample Project.
  • Gemtec’s Engineering Team will be conducting its final site visit today with its UAV drone to complete Lidar mapping and site design analysis.
  • Nine Mile Metals will submit its Bulk Sample Permit filing next week once the Engineering Site Plan is received.
  • Nine Mile Metals has selected its vendors of choice for the site plan excavation and processing stages.

Schrödinger Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Software, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Technology, Clinical Trials, United European Gastroenterology, PH, PRMT5, Trial of the century, Global health, IND, Acute myeloid leukemia, MALT1, Food, PKA, FEP, Myelodysplastic syndrome, Regulation of tobacco by the U.S. Food and Drug Administration, GAAP, Mantle cell lymphoma, Research, Bill, Ulcerative colitis, Bill & Melinda Gates Foundation, Pharmacokinetics, CDC7, Phases of clinical research, Webcast, ADMET, UEG, Safety, Overweight, Therapy, Investment, Table, Patient, Cryptocurrency, Pharmaceutical industry, Bank, EU

Schrödinger today updated its financial guidance for 2023.

Key Points: 
  • Schrödinger today updated its financial guidance for 2023.
  • The Phase 1 dose-escalation study in healthy volunteers is nearing completion, and the company expects to report data from the study in the fourth quarter of 2023.
  • Schrödinger will host a conference call to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 4:30 p.m.
  • Schrödinger will host its Pipeline Day in New York City on Thursday, December 14, 2023, beginning at 10:00 a.m.

United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis

Retrieved on: 
Tuesday, October 31, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, United Therapeutics, FDA, Pulmonary fibrosis, Respiratory failure, Food, Associate Director of National Intelligence and Chief Information Officer, PPF, Idiopathic pulmonary fibrosis, Orthostatic hypertension, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phenotype, Exercise, IPF, FVC, Targanta Therapeutics Corporation, UTHR, Pharming, Disease, PH, Pulmonary hypertension, ILD, Blood, Therapy, Inova Fairfax Hospital, Patient, Death, Pharmaceutical industry, Treprostinil

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution in 698 adult patients with progressive pulmonary fibrosis (PPF).

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution in 698 adult patients with progressive pulmonary fibrosis (PPF).
  • This is in addition to two separate ongoing registration-phase studies, TETON 1 and TETON 2, of nebulized Tyvaso in patients with another type of pulmonary fibrosis (PF) known as idiopathic pulmonary fibrosis (IPF).
  • The 52-week study will evaluate the impact of nebulized Tyvaso on a key prognostic indicator for PPF known as forced vital capacity (FVC).
  • The TETON PPF study seeks to evaluate the use of nebulized Tyvaso in PPF patients irrespective of whether or not they have PH.

North Carolina fertility practice introduces AI powered embryo selection

Retrieved on: 
Thursday, November 2, 2023
Child, United Kingdom, Intelligence, Genetic testing, Fertility, III, Reach, Health, Fertilisation, Multimedia, IVF, PH, Partnership, Reproductive medicine, AI, Patient, Mineral oil, Birth control, Medical device

CHARLOTTE, N.C., Nov. 2, 2023 /PRNewswire/ -- Reach Fertility, a leading fertility treatment and research practice, has recently added Caremaps-AI® as part of their service for all in vitro fertilization patients. In December of 2023, Reach announced its partnership with CARE Fertility, a world-renowned pioneering fertility group based in the United Kingdom. With this partnership, Reach joins a research-focused fertility network with access to the most advanced reproductive science technology. 

Key Points: 
  • CHARLOTTE, N.C., Nov. 2, 2023 /PRNewswire/ -- Reach Fertility, a leading fertility treatment and research practice, has recently added Caremaps-AI® as part of their service for all in vitro fertilization patients.
  • In December of 2023, Reach announced its partnership with CARE Fertility, a world-renowned pioneering fertility group based in the United Kingdom.
  • With this partnership, Reach joins a research-focused fertility network with access to the most advanced reproductive science technology.
  • These images combined with AI analysis, remove human subjectivity from embryo assessment and allow embryologists to select the embryo with the highest chance of becoming a healthy baby.

LI-COR Environmental Purchases Apollo SciTech Assets

Retrieved on: 
Wednesday, November 1, 2023
PH, PCO2, Apollo, Carbon, Atmosphere, Biophysical environment, LI-COR, LINCOLN, Research, Battery Ventures, CO2, Partial pressure, Ocean, DIC, Climate change, Agriculture, Talk

LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.

Key Points: 
  • LI-COR, a leader in environmental measurement technology, extends its reach to the oceans with the purchase of Apollo SciTech assets.
  • LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.
  • Apollo SciTech instruments are used worldwide.
  • Two of Apollo SciTech's top-selling assets—the dissolved inorganic carbon (DIC) analyzers and the partial pressure of CO2 (pCO2) models—currently incorporate LI-COR technology.

LI-COR Environmental Purchases Apollo SciTech Assets

Retrieved on: 
Wednesday, November 1, 2023
PH, PCO2, Apollo, Carbon, Atmosphere, Biophysical environment, LI-COR, LINCOLN, Research, Battery Ventures, CO2, Partial pressure, Ocean, DIC, Climate change, Fossil fuel, Talk

LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.

Key Points: 
  • LI-COR, a leader in environmental measurement technology, extends its reach to the oceans with the purchase of Apollo SciTech assets.
  • LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.
  • LI-COR, a leader in greenhouse gas measurement technology, extends to the oceans with purchase of Apollo SciTech assets.
  • Apollo SciTech, founded in 2001, produces high-quality instruments that use carbon dioxide parameters (DIC, TAlk, pH, and pCO2) as measures of biological activity in aquatic environments.

Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association Provide Guidance on Pulmonary Hypertension Related to Interstitial Lung Disease

Retrieved on: 
Wednesday, October 25, 2023
Pulmonary hypertension, PHA, Pulmonary fibrosis, Health care, Pulmonary Hypertension Association, Lung transplantation, Cystic Fibrosis Foundation, Quality of life, Tissue, PF, Disease, Heart, Risk, PH, ILD, CMO, Patient, Diagnosis, PFF, Pharmaceutical industry, Medical imaging

CHICAGO, Oct. 25, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the screening, diagnosis and treatment of patients living with pulmonary hypertension (PH) related to interstitial lung disease (PH-ILD).

Key Points: 
  • CHICAGO, Oct. 25, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the screening, diagnosis and treatment of patients living with pulmonary hypertension (PH) related to interstitial lung disease (PH-ILD).
  • The PH-ILD position statement, featuring a version for patients and a version for healthcare providers, reflects input from experts in interstitial lung disease (ILD), PH, PH-ILD and patient representatives.
  • More than 250,000 Americans are living with pulmonary fibrosis (PF) and ILD.
  • PF, a form of ILD, can have many causes and they can all be associated with PH.